~ Buy the MANNITOL Drug Excipient Business Development Opportunity Report, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR MANNITOL

All Clinical Trials for mannitol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003062 ↗	Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 2	1997-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effect of temozolomide in patients with progressive or recurrent stage IV non-small cell lung cancer, with or without brain metastases, who have not been treated for metastatic disease with chemotherapy.
NCT00004767 ↗	Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders	Completed	Johns Hopkins University	Phase 2	1985-01-01	OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00004767 ↗	Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders	Completed	National Center for Research Resources (NCRR)	Phase 2	1985-01-01	OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00111956 ↗	Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome	Completed	Massachusetts General Hospital	Phase 2/Phase 3	2004-04-01	Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.
NCT00111956 ↗	Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2/Phase 3	2004-04-01	Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.

Clinical Trial Conditions for mannitol

Condition Name

Condition Name for mannitol
Intervention	Trials
Asthma	20
Cystic Fibrosis	10
Healthy	7
Traumatic Brain Injury	6

Condition MeSH

Condition MeSH for mannitol
Intervention	Trials
Asthma	23
Intracranial Hypertension	12
Fibrosis	10
Cystic Fibrosis	10

Clinical Trial Locations for mannitol

Trials by Country

Trials by Country for mannitol
Location	Trials
United States	137
Canada	38
United Kingdom	35
Australia	34
Italy	20

Trials by US State

Trials by US State for mannitol
Location	Trials
New York	19
Massachusetts	12
Minnesota	9
Oregon	8
Ohio	7

Clinical Trial Progress for mannitol

Clinical Trial Phase

Clinical Trial Phase for mannitol
Clinical Trial Phase	Trials
Phase 4	37
Phase 3	34
Phase 2/Phase 3	10

Clinical Trial Status

Clinical Trial Status for mannitol
Clinical Trial Phase	Trials
Completed	132
Unknown status	27
Not yet recruiting	18

Clinical Trial Sponsors for mannitol

Sponsor Name

Sponsor Name for mannitol
Sponsor	Trials
Pharmaxis	19
Northwell Health	7
Ain Shams University	6

Sponsor Type

Sponsor Type for mannitol
Sponsor	Trials
Other	366
Industry	64
NIH	17